OPNT: Increased Revenue Guidance for NARCAN® Nasal Spray…

By David Bautz, PhD

NASDAQ:OPNT

READ THE FULL OPNT RESEARCH REPORT

Financial Update

On August 8, 2019, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the second quarter of 2019. The company recorded a total of $6.8 million in revenue for the three months ending June 30, 2019, which consisted of $6.1 million in royalty revenue from the sale of NARCAN® Nasal Spray, $0.1 million from grant and contract revenue, and $0.6 million from treatment investment revenue. This compares to royalty revenue of $3.1 million for the three months ending June 30, 2018. The increase was attributable to an increase in sales of NARCAN® Nasal Spray by Emergent BioSolutions (EBS), which totaled $73 million in the second quarter of 2019. This was ahead of our estimate

... read more at: https://finance.yahoo.com/news/opnt-increased-revenue-guidance-narcan-141000008.html

by

Leave a Reply